All News

Proposed rules from the Health Resources and Services Administration to make children's hospitals eligible for 340B are moving slowly. And final rules from the Centers for Medicare and Medicaid Services will boost costs while cutting reimbursement.

The National Comprehensive Cancer Network recently updated its guidelines for Non-Hodgkin's Lymphoma to include new therapeutic options, as well as changes to diagnostic criteria and staging.

The four leading infusion pump manufacturers all report brisk sales of smart pumps, but many users are evading the software dosing safeguards that make pumps smart.

Ready or not, electonic pedigree is coming. But bumps in the road area already rocking the pharmaceutical world. The biggest bump: vague definitions and conflicting exptectations.

CMS announced that it would release NPI number data beginning Sept. 4, at which point all data that are disclosable under the Freedom of Information Act will be made available to the public.

Products encompassing newly approved Rx drugs and generics, plus health and beauty care, home health care, and other items.

While drug-resistant infections have been multiplying, there has been a mere trickle of new antibiotics coming down the pipeline. The tide may be changing; there are 30 or more antibiotics in development.

The Centers for Medicare and Medicaid Services has come out with new, less stringent rules on the coverage of two popular anemia drugs. The new rules apply mostly to cancer patients who receive chemotherapy that causes anemia and people with the bone marrow disorder myelodysplasia.

Chains should not have been the only ones contacted about the issue of drug errors. Pharmacists should also have been consulted about ways to error proof pharmacies.